South & Central America Mid-Size Pharmaceutical Market

The mid-size pharmaceutical market in South & Central America is expected to grow from US$ 24,301.56 million in 2022 to US$ 31,118.17 million by 2028; it is estimated to grow at a CAGR of 4.2% from 2022 to 2028.

The South & Central America mid-size pharmaceutical market is segmented into Brazil, Argentina, and the Rest of South & Central America. In the global market, SAM held the second smallest share of US$ 24,301.56 million in 2022. The growth of the SAM market is driven by the increasing prevalence of cancer, rising geriatric population, surging incidence of hypertension, and the growing prevalence of other chronic diseases. The mid-size pharmaceutical market in the Rest of South & Central America is sub segmented into Peru, Chile, Bolivia, Ecuador, and other countries. According to the GLOBOCAN 2020, prostate cancer is the leading cause of cancer death in the Peruvian population, with an age-standardized mortality rate (ASMR) of 44.3 per 100,000. Due to the rising cancer prevalence, the demand for oncology drugs is expected to rise in the region, which would create lucrative opportunities for the mid-size pharmaceutical companies.

By introducing new features and technologies, vendors in the South & Central America mid-size pharmaceutical market can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the market growth at a good CAGR during the forecast period.

South & Central America Mid-Size Pharmaceutical

Market Revenue and Forecast to 2028 (US$ Million)

South & Central America Mid-Size Pharmaceutical Strategic Insights

Strategic insights for the South & Central America Mid-Size Pharmaceutical provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

South & Central America Mid-Size Pharmaceutical Report Scope

South & Central America Mid-Size Pharmaceutical Regional Insights

The geographic scope of the South & Central America Mid-Size Pharmaceutical refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

South & Central America Mid-Size Pharmaceutical Market Segmentation

The South & Central America mid-size pharmaceutical market is segmented on the basis of type, drug development type, formulation, therapy class, and country.

Based on type, the South & Central America mid-size pharmaceutical market is bifurcated into prescription and over-the-counter. In 2022, the over-the-counter segment accounted for a larger market share. Based on drug development type, the market is bifurcated into in-house and outsource. The outsource segment held a larger market share in 2022. Based on formulation, the South & Central America mid-size pharmaceutical market is segmented into tablets and capsules, injectables, sprays, and other formulations. The tablets & capsules segment held the largest market share in 2022. Based on therapy class, the market is segmented into cardiovascular diseases, pain management, diabetes, cancer, and other conditions. The diabetes segment held the largest market share in 2022. Based on country, the South & Central America mid-size pharmaceutical market is segmented into Brazil, Argentina, and Rest of South & Central America. Brazil held the largest market share in 2022.

Alexion Pharmaceuticals, Inc.; Bausch Health Companies Inc.; Daiichi Sankyo Company Limited; Endo Pharmaceuticals Inc.; Mallinckrodt; and Sun Pharmaceutical Industries Ltd are among the leading companies operating in the mid-size pharmaceutical market in the region.